Trials / Completed
CompletedNCT04444050
Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants
Randomized, Double-Blind, Placebo-Controlled Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986331 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effects of single and multiple oral doses of BMS-986331 versus placebo in healthy participants and healthy Japanese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986331 | Specified dose on specified days |
| OTHER | Placebo, Matching BMS-986331 | Specified dose on specified days |
Timeline
- Start date
- 2020-06-23
- Primary completion
- 2021-05-19
- Completion
- 2021-05-19
- First posted
- 2020-06-23
- Last updated
- 2022-10-20
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04444050. Inclusion in this directory is not an endorsement.